Inmune Bio, Inc. (INMB) stock
INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.96+0.01 (+1.44%)
Close on Nov 17, 2026Market cap $26.64MP/E –Yield –
Inmune Bio operating margin
Operating margin is operating income as a percentage of revenue.
Inmune Bio's operating margin for the twelve months ending Dec 31, 2025 was -94766.0%. For fiscal 2025 it was -94766.0%, against -304535.7% the year before. The highest annual figure on record is -6938.8% in fiscal 2022.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -94766.0% | +209769.7 |
| FY2024 | Dec 31, 2024 | -304535.7% | −285348.0 |
| FY2023 | Dec 31, 2023 | -19187.7% | −12249.0 |
| FY2022 | Dec 31, 2022 | -6938.8% | +9167.9 |
| FY2021 | Dec 31, 2021 | -16106.6% | +95057.0 |
| FY2020 | Dec 31, 2020 | -111163.6% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2025 | Mar 31, 2025 | -19810.0% | −5873.0 |
| Q1 FY2024 | Mar 31, 2024 | -78692.9% | −61790.2 |
| Q4 FY2023 | Dec 31, 2023 | -29925.0% | −24108.5 |
| Q3 FY2023 | Sep 30, 2023 | -19832.6% | −12237.7 |
| Q2 FY2023 | Jun 30, 2023 | -13937.0% | +25988.0 |
| Q1 FY2023 | Mar 31, 2023 | -16902.6% | −12928.4 |
| Q4 FY2022 | Dec 31, 2022 | -5816.5% | −276.6 |
| Q3 FY2022 | Sep 30, 2022 | -7594.9% | +56840.8 |
| Q2 FY2022 | Jun 30, 2022 | -39925.0% | +73775.0 |
| Q1 FY2022 | Mar 31, 2022 | -3974.2% | – |
| Q4 FY2021 | Dec 31, 2021 | -5539.9% | – |
| Q3 FY2021 | Sep 30, 2021 | -64435.7% | – |
| Q1 FY2021 | Mar 31, 2021 | -113700.0% | – |
See a number that looks wrong?